Group 1 - The Shenzhen Stock Exchange issued a regulatory letter to Zhejiang Liansheng Chemical Co., Ltd. regarding violations related to the management of raised funds, including purchasing financial products before the approval period and exceeding authorized limits [1] - The company reported inaccuracies in the disclosure of large time deposits in its special reports for the half-year and annual periods of 2023 and 2024 [1] - Key executives, including the chairman and general manager, failed to fulfill their duties and obligations, leading to violations of the listing rules [1] Group 2 - As of the report date, the market capitalization of Liansheng Chemical is 3 billion yuan [2] - The company's revenue composition for the year 2024 is entirely from fine chemicals, accounting for 100% [1]

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Liansheng Chemical, indicating a significant level of financing activity and a stable growth in revenue and profit [1][2]. - On August 28, Liansheng Chemical's stock fell by 1.56%, with a trading volume of 57.99 million yuan. The financing buy-in amount was 7.56 million yuan, while the financing repayment was 4.68 million yuan, resulting in a net financing buy-in of 2.88 million yuan [1]. - As of August 28, the total balance of margin trading for Liansheng Chemical was 52.19 million yuan, accounting for 1.82% of its market capitalization, which is above the 90th percentile level over the past year [1]. Group 2 - As of June 30, the number of shareholders for Liansheng Chemical was 8,697, an increase of 2.52% from the previous period. The average circulating shares per person rose to 10,779 shares, an increase of 238.68% [2]. - For the first half of 2025, Liansheng Chemical reported a revenue of 343 million yuan, representing a year-on-year growth of 13.95%. The net profit attributable to the parent company was 18.02 million yuan, reflecting a year-on-year increase of 9.61% [2]. - Since its A-share listing, Liansheng Chemical has distributed a total of 97.52 million yuan in dividends, with 75.38 million yuan distributed over the past three years [3].

Core Viewpoint - The recent financial report of Liansheng Chemical (301212) shows a year-on-year increase in total revenue and net profit, but a decline in quarterly performance, highlighting concerns over accounts receivable and cash flow [1][4]. Financial Performance - Total revenue for the first half of 2025 reached 343 million yuan, a 13.95% increase compared to 301 million yuan in the same period of 2024 [1]. - Net profit attributable to shareholders was 18.02 million yuan, up 9.61% from 16.44 million yuan in the previous year [1]. - The gross margin decreased to 12.67%, down 4.93% year-on-year, while the net margin fell to 5.42%, a decline of 5.25% [1]. - The total of selling, administrative, and financial expenses was 14.44 million yuan, representing 4.21% of revenue, an increase of 34.68% year-on-year [1]. Cash Flow and Receivables - The company reported a significant accounts receivable level, with accounts receivable amounting to 95.82 million yuan, which is 555.2% of the net profit for the latest annual report [1][4]. - Operating cash flow per share improved to 0.47 yuan, a substantial increase of 146.47% compared to -1.01 yuan in the previous year [1]. Business Model and Industry Outlook - The company's return on invested capital (ROIC) was 0.34% last year, indicating weak capital returns, while the historical median ROIC since listing is 12.26% [3]. - The chemical industry has shown signs of recovery, with improved market demand for major products, although the pace of recovery varies across different segments [5]. - The company plans to enhance production efficiency and optimize existing product processes while advancing new biodegradable materials to diversify its product offerings and create new profit growth points [5].

Core Insights - Liansheng Chemical (301212.SZ) reported a total operating revenue of 343 million yuan for the first half of 2025, an increase of 41.98 million yuan or 13.95% compared to the same period last year [1] - The net profit attributable to shareholders was 18.02 million yuan, up by 1.58 million yuan or 9.61% year-on-year [1] Financial Performance - The company achieved a net cash inflow from operating activities of 50.66 million yuan, ranking 51st among disclosed peers, with an increase of 160 million yuan compared to the same period last year [1] - The latest debt-to-asset ratio is 19.04%, ranking 31st among peers, with a decrease of 0.22 percentage points from the previous quarter [3] - The gross profit margin is 12.67%, up by 0.05 percentage points, marking two consecutive quarters of increase [3] - Return on equity (ROE) stands at 1.33%, an increase of 0.10 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 0.17 yuan, an increase of 0.02 yuan or 13.33% compared to the same period last year [3] - The total asset turnover ratio is 0.20 times, an increase of 0.02 times or 11.92% year-on-year [3] - The inventory turnover ratio is 3.13 times, ranking 34th among peers, with an increase of 0.95 times or 43.53% year-on-year [3] Shareholder Structure - The number of shareholders is 8,697, with the top ten shareholders holding 83.76 million shares, accounting for 77.56% of the total share capital [3] - The largest shareholder is Liansheng Chemical Group Co., Ltd., holding 52.7% of the shares [3]

Core Viewpoint - Liansheng Chemical (301212.SZ) reported its semi-annual results for 2025, indicating significant institutional investor interest with a total holding of 62 million shares, representing 57.41% of the company's total equity [1] Group 1 - As of August 26, 2025, there are two institutional investors disclosing their holdings in Liansheng Chemical A-shares [1] - The institutional investors include Liansheng Chemical Group Co., Ltd. and Taizhou Gaosheng Investment Partnership (Limited Partnership) [1] - The total proportion of shares held by institutional investors remains unchanged at 57.41% [1]

Core Insights - Liansheng Chemical reported a revenue of 343 million yuan for the first half of 2025, representing a year-on-year growth of 13.95% [1] - The net profit attributable to shareholders of the listed company was 18.02 million yuan, an increase of 9.61% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 16.04 million yuan, reflecting a year-on-year growth of 11.35% [1] - The basic earnings per share stood at 0.17 yuan [1]

证券代码：301212 证券简称：联盛化学 公告编号：2025-034 浙江联盛化学股份有限公司 2025 年半年度募集资金存放、管理与使用情况的专项报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 (一)募集资金管理情况 为规范募集资金的管理和使用，提高资金使用效率和效益，保护投资者权益， 公司按照《中华人民共和国公司法》《中华人民共和国证券法》和《深圳证券交易所 上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律、法规和 规范性文件的规定，结合公司实际情况，制定了《募集资金管理制度》。 根据《上市公司募集资金监管规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》及《深圳证券交易所创业板上市公司自律监管指 南第 2 号——公告格式》等法律法规的规定，浙江联盛化学股份有限公司(以下简称 "公司"或"本公司")编制了 2025 年半年度募集资金存放、管理与使用情况的专 项报告，具体情况如下: 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证监会以"证监许可〔2022〕413 号"文批复同意， ...

法定代表人： 主管会计工作的负责人： 会计机构负责人： 浙江联盛化学股份有限公司 2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位：万元 | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 司的关联关系 | 上市公司核算 的会计科目 | 2025年期初 占用资金余额 | 2025年半年度占 用累计发生金额 | 2025年半年度占 用资金的利息 | 2025年半年度 偿还累计发生 | 2025年半年度期 末 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | （不含利息） | （如有） | 金额 | 占用资金余额 | | | | 控股股东、实际控制人及其附 | | | | | | | | | | | | 属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | | | | 前控股股东、实际控制人及其 附属企业 | | | | | | | | | | | | 小 计 | | | | | | | | | ...

证券代码：301212 证券简称：联盛化学 公告编号：2025-031 浙江联盛化学股份有限公司（以下简称"公司"）于 2025 年 8 月 25 日召开 第四届董事会第三次会议、第四届监事会第三次会议，审议通过了《关于公司 <2025 年半年度报告>及其摘要的议案》。 为使投资者全面了解公司的经营成果和财务状况，公司于 2025 年 8 月 27 日在深圳证券交易所网站（www.szse.cn）及巨潮资讯网（www.cninfo.com.cn） 上披露了《浙江联盛化学股份有限公司 2025 年半年度报告》和《浙江联盛化学 股份有限公司 2025 年半年度报告摘要》，敬请投资者注意查阅。 特此公告。 浙江联盛化学股份有限公司 董事会 2025 年 8 月 27 日 浙江联盛化学股份有限公司 2025 年半年度报告披露提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 ...

证券代码：301212 证券简称：联盛化学 公告编号：2025-030 浙江联盛化学股份有限公司 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江联盛化学股份有限公司（以下简称"公司"）第四届监事会第三次会议（以 下简称"本次会议"）于 2025 年 8 月 25 日在公司会议室以现场的方式召开。会议通 知于 2025 年 8 月 15 日以书面、邮件（电子邮件）或电话等方式送达给各位监事。本 次会议应出席监事 3 名，实际出席监事 3 名，本次会议由监事会主席黄卫国先生主持， 董事会秘书列席了会议。本次会议的召集、召开及表决程序符合《中华人民共和国公 司法》《中华人民共和国证券法》等有关法律、行政法规、规范性文件、部门规章及 《浙江联盛化学股份有限公司章程》（以下简称"《公司章程》"）的相关规定，会 议形成的决议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，形成如下决议： (一)审议通过了《关于公司<2025 年半年度报告>及其摘要的议案》 经审议：监事会认为公司 2025 年半年度报告及其摘要的编制和审议程序符合相 ...